• 諮詢熱線+852 3480 8393

Logo
  • 首頁
  • 公司介紹
    • 背景
    • 免疫治療日本
    • 免疫治療香港
    • 腫瘤科醫生
  • 免疫細胞治療
    • 免疫細胞治療/自體免疫療法
    • 樹突狀細胞/DC疫苗療法
    • 自然殺傷細胞/NK細胞療法
    • 淋巴因子活化殺傷細胞(殺手T細胞)療法
    • 免疫治療成功率
    • 免疫治療副作用
    • 免疫治療費用
  • 醫生介紹
    • 日本
  • 治療成果
  • 癌症預防/防復發
    • 癌症復發率
    • 癌症預防
  • 最新資訊
    • 新聞
    • 臨床醫學報告
  • 聯絡我們

最新資訊

  • 首頁
  • 最新資訊
  • 臨床醫學報告
首頁 > 最新資訊 > 臨床醫學報告 > Targeted Cancer Therapy by Dendritic Cell Vaccine

Targeted Cancer Therapy by Dendritic Cell Vaccine

  • Cancer Treatment
  • 2022-06-17
  • 0 次瀏覽

https://www.intechopen.com/chapters/41975 


Abstract

The unpredictability of efficacy and toxicity of treatment are limitations of current standard cancer treatments. The clinical results obtained by standard therapies suggest a need for a paradigm change in cancer treatment. In recent years, immune cell therapy has been in the spotlight with the expectation of opening the door to a new area of cancer therapy. Targeted cancer therapy, which selectively takes action against targets expressed in the tumor surface, seems to be promising.

The immune system can control various types of tumors. Antigen-non-specific innate immunity and antigen-specific adaptive immunity can reject tumors.

The identification of tumor antigens recognized by T cells has facilitated the development of immune cell therapy in clinical oncology. The dendritic cell based cancer vaccine aims to induce tumor specific effector T cells (cytotoxic T lymphocyte, CTL) that can reduce tumor mass as well as tumor specific memory T cells that can control tumor relapse.

In this text, immune cell target therapy in clinical oncology will be discussed and hopefully this will be helpful in daily clinical practice.


Source: Abe, H. et al., 2013, 'Targeted Cancer Therapy by Dendritic Cell Vaccine', in L. Rangel (ed.), Cancer Treatment - Conventional and Innovative Approaches, IntechOpen, London. 10.5772/55450.


上一篇:Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment 下一篇:NK cell-based cancer immunotherapy: from basic biology to clinical development

欄目分類

  • 新聞 16
  • 臨床醫學報告 13

最新文章

  • Targeting dendritic cells in pancreatic ductal adenocarcinoma
    2022-06-17
  • Modified Immunotherapy Approach Shows Promise for Leukemia Subscribe
    2022-06-17
  • Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma
    2022-06-17
  • WT1 (Wilms' Tumor Gene 1): Biology and Cancer Immunotherapy
    2022-06-17
  • NK cell-based cancer immunotherapy: from basic biology to clinical development
    2022-06-17
  • Targeted Cancer Therapy by Dendritic Cell Vaccine
    2022-06-17
  • Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment
    2022-06-17
  • Antigen presentation by dendritic cells and their instruction of CD4+ T helper cell responses
    2022-06-17
  • Dendritic Cell–Based Immunotherapy: State of the Art and Beyond
    2022-06-17
  • Review of Dendritic Cells, Their Role in Clinical Immunology, and Distribution in Various Animal Species
    2022-06-17
  • Improved survival ratios correlate with myeloid dendritic cell restoration in acute-on-chronic liver failure patients receiving methylprednisolone therapy
    2022-05-05
  • Effect of cytokine‑induced killer cells combined with dendritic cells on the survival rate and expression of 14‑3‑3ζ and p‑Bad proteins in Lewis lung cancer cell lines
    2022-05-05
  • Cancer immunotherapy via dendritic cells
    2022-05-05
所有文章
Logo
  • 郵箱:info@asiaimmune.com
  • 電話:+852 3480 8393
  • 微信:aicl_hk

免疫細胞治療

  • 免疫細胞治療/自體免疫療法
  • 樹突狀細胞/DC疫苗療法
  • 自然殺傷細胞/NK細胞療法
  • 淋巴因子活化殺傷細胞(殺手T細胞)療法
  • 免疫治療成功率
  • 免疫治療副作用
  • 免疫治療費用

公司地址

  • 九龍尖沙咀漢口道28號亞太中心8樓812室
  • +852 3480 8393

Copyright © 2022. Designed by Asia Immunotherapy Company Limited.